Methods of delivering an agent to the eye

Patent metadata

Field	Value
Publication number	US-2021196508-A1
Application number	US-202117140505-A
Country	US
Kind code	A1
Filing date	Jan 4, 2021
Priority date	May 7, 2015
Publication date	Jul 1, 2021
Grant date	—

Abstract

Methods of delivering agents to structures within the eye are provided.

First claim

1 . A method of delivering an agent to the retina, the method comprising:
removing at least a portion of the vitreous fluid from the eye; removing at least a portion of the inner limiting membrane (ILM) to expose a section of the retina; introducing a non-diluting, fluid replacement material into the eye; applying a composition comprising an agent to the exposed section of the retina; and maintaining the position of the agent on the exposed retina for a time sufficient to allow the agent to enter cells in the retina; thereby delivering the agent to the retina.

2 - 4 . (canceled)

5 . The method of claim 1 , further comprising introducing a fluid detection agent into the eye prior to or during the step of removing at least a portion of the fluid from the eye.

6 . The method of claim 5 , wherein the fluid detection agent is triamcinolone.

7 . The method of claim 1 , wherein the portion of the ILM is surgically or enzymatically removed.

8 - 9 . (canceled)

10 . The method of claim 1 , wherein the portion of the ILM that is removed is from about 0.62 mm 2 to about 62 mm 2 .

11 . The method of claim 1 , wherein the ILM is visualized with an ILM-visualization material.

12 . The method of claim 11 , wherein the ILM-visualization material is indocyanine green (ICG).

13 . (canceled)

14 . The method of claim 1 , wherein the composition comprises from about 50% to about 95% of the agent.

15 . The method of claim 1 , wherein the composition further comprises a viscoelastic composition.

16 . The method of claim 1 , wherein the agent is selected from the group consisting of a viral delivery vector, a non-viral delivery vector, an antibody, a cell, a small molecule, a nanoparticle, or combinations thereof.

17 . The method of claim 16 , wherein the viral delivery vector is selected from the group consisting of adeno-associated virus (AAV), ancestral AAV, adenovirus, lentivirus, retrovirus, herpes simplex virus (HSV), and baculovirus.

18 . The method of claim 1 , wherein the non-diluting, fluid replacement material is selected from the group consisting of C3F8, SF6, air, nitrogen, oxygen, perfluoro-n-octane, and silicone oil.

19 . (canceled)

20 . The method of claim 1 , wherein the maintaining step comprises maintaining the position of the agent on the exposed retina for at least about 30 minutes.

21 . (canceled)

22 . The method of claim 1 , wherein the maintaining step comprises maintaining a subject in a supine or prone position.

23 . (canceled)

24 . A method of delivering an agent to a structure in the eye, the method comprising:
removing at least a portion of an eye fluid that contacts or covers a structure in the eye to expose a section of the structure; introducing a non-diluting, fluid replacement material into the eye; applying a composition comprising an agent to the exposed section of the structure; and maintaining the position of the agent on the structure for a time sufficient to allow the agent to enter cells in the structure; thereby delivering the agent to the structure in the eye.

25 . The method of claim 24 , wherein the eye fluid comprises aqueous humour or vitreous fluid.

26 - 28 . (canceled)

29 . The method of claim 24 , further comprising introducing a fluid detection agent into the eye prior to or during the step of removing at least a portion of the eye fluid.

30 . The method of claim 24 , wherein the agent is selected from the group consisting of a viral delivery vector, a non-viral delivery vector, an antibody, a cell, a small molecule, a nanoparticle, or combinations thereof.

31 . The method of claim 30 , wherein the viral delivery vector is selected from the group consisting of adeno-associated virus (AAV), ancestral AAV, adenovirus, lentivirus, retrovirus, herpes simplex virus (HSV), and baculovirus.

32 . The method of claim 24 , wherein the non-diluting, fluid replacement material is selected from the group consisting of C3F8, SF6, air, nitrogen, oxygen, perfluoro-n-octane, and silicone oil.

Assignees

• Massachusetts Eye & Ear Infirmary

Inventors

• Comander Jason
• Eliott Dean
• Kim Leo
• Vandenberghe Luk H

Classifications

• A61K49/0034

  Indocyanine green, i.e. ICG, cardiogreen · CPC title

• A61F9/00736

  Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments (A61F9/008 takes precedence) · CPC title

• A61F9/0008 Primary

  Introducing ophthalmic products into the ocular cavity or retaining products therein (putting in contact lenses A61F9/0061; introducing or retaining media in cavities of the body in general A61M31/00) · CPC title

• A61K49/006

  Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery · CPC title

• C12N2750/14242

  virus or viral particle as vehicle, e.g. encapsulating small organic molecule · CPC title